Growing calls for release of vaccine data guidelines that are changing the market Business

Pressure is mounting for clear guidelines on publishing information on the vaccine trial market, after Moderna’s data was informed ahead of its official release.

Moderna and Pfizer caused massive spikes in stock prices in the stock markets earlier this month when they each announced they were set to launch a coronavirus vaccine.

There are no formal rules governing how publicly traded or private pharmaceutical companies disseminate clinical trial results.

Currently, the data could be published in a scientific journal for peer review, unveiled at a conference, or published through the market’s Regulatory Information Service (RNS).

However, a chief executive of a large publicly traded healthcare company said that while different companies take different approaches, data on market developments should first be made public through the RNS.

“In general, while data can be extremely important to a specific business, it doesn’t move the market. But with Covid vaccines, there has never been clinical trial data with more potential to move markets than the vaccine data we just saw, ”he said.

“The nature of this data is analogous to central bank interest rate decisions. This is a unique situation and raises some interesting questions. “